Global Acute Heart Failure (AHF)Market
The global acute heart failure market is estimated to be worth over USD 2622.8 Mnin 2033 and is expected to grow at CAGR of 25.5% during the forecast period (2024-2033). Acute heart failure (AHF) is a serious condition marked by the abrupt onset or worsening of symptoms, such as fatigue, fluid retention, and shortness of breath, owing to the heart's inadequacy to pump blood efficiently. This condition offers a significant global health burden, with growing incidences owing to factors like an aging population, lifestyle-related diseases, and the increasing prevalence of cardiovascular risk factors. In the past few years, the global market for acute heart failure has undergonenotableprogress, led by upgrades in treatment modalities, a greater understanding of cardiovascular physiology, and a soaringfocus on precision medicine.
Leading players in the acute heart failure market are actively engaged in research and development to introduce innovative therapeutic solutions. Considerable developments include the introduction of novel medications, such as sacubitril/valsartan, which has illustratedefficiency in mitigating cardiovascular mortality and hospitalizations. Along with that, innovations in digital health technologies, exemplified by remote patient monitoring and telemedicine, are redefining the outlook by providing more comprehensive and patient-centric approaches to acute heart failure management.
Key pharmaceutical companies, including Johnson & Johnson, Novartis, and AstraZeneca, are in the lead of encouragingadvancements in the acute heart failure space. Collaborations between industry leaders, academic institutions, and healthcare providers further contribute to the market's dynamic growth. As the global healthcare community increasingly recognizes the importance of addressing acute heart failure, the market is estimated to behold sustained expansion, with an aim on developing targeted therapies, enhancing patient outcomes, and improving overall quality of life for those affected by this severe cardiovascular condition.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:
A preface providing an introduction to the full report, acute heart failuremarket, 2023-2033.
An outline of the systematic research methodology adopted to conduct the study on acute heart failuremarket, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
An overview of economic factors that impact the overall acute heart failuremarket, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
An executive summary of the insights captured during our research, offering a high-level view of the current state of the acute heart failuremarket and its likely evolution in the mid-to-long term.
A brief introduction to the acute heart failure, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using Acute heart failure.
A detailed assessment of the market landscape of acute heart failurethat are either approved or being evaluated in different stages of development, based on several relevant parameters, such as By Disorder Type (Right-sided Heart Failure, Left-sided Heart Failure (Systolic Failure, Diastolic Failure), Congestive Heart Failure), By Drug Category (Angiotensin-Converting Enzyme (ACE) Inhibitors (Captopril (Capoten), Enalapril (Vasotec), Fosinopril (Monopril), Lisinopril (Prinivil, Zestril), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), Others), Angiotensin II Receptor Blockers (Candesartan (Atacand), Losartan (Cozaar), Valsartan (Diovan)), Angiotensin-Receptor Neprilysin Inhibitors (ARNIs) (Sacubitril/valsartan), If Channel Blocker (Ivabradine (Corlanor)), Beta Blockers (Bisoprolol (Zebeta), Metoprolol Succinate (Toprol XL), Carvedilol (Coreg), Others), Aldosterone Antagonists (Spironolactone (Aldactone), Eplerenone (Inspra), Diuretics, Furosemide (Lasix), Bumetanide (Bumex), Torsemide (Demadex), Chlorothiazide (Diuril)), Amiloride (Midamor Chlorthalidone (Hygroton) (Hydrochlorothiazide or HCTZ (Esidrix, Hydrodiuril), Others), Anticoagulants (Blood Thinners) (Cholesterol Lowering Drugs (Statins), Digoxin)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). Further, the chapter features analysis on key niche market segments. In addition, the chapter features analysis of various acute heart failure developers, based on their year of establishment, company size, location of headquarters and most active players.
An in-depth analysis of partnerships and collaborations that have been inked between various stakeholders, since 2019, based on several relevant parameters, such as the year of partnership, type of partnership, focus of partnership, purpose of partnership, therapeutic applications and most active players (in terms of number of partnerships). It also highlights the regional distribution of partnership activity in this market.
A detailed analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of HPAPIs, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
An in-depth analysis of the various acute heart failurefocused initiatives undertaken by big market players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.
One of the key objectives of this market report was to estimate the current market size and the future growth potential of the acute heart failureover the forecast period. Based on several parameters, such as regional analysis as well as segmental analysis rates, we have developed informed estimates of the likely evolution of the acute heart failuremarket over the forecast period 2023-2033. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as By Disorder Type (Right-sided Heart Failure, Left-sided Heart Failure (Systolic Failure, Diastolic Failure), Congestive Heart Failure), By Drug Category (Angiotensin-Converting Enzyme (ACE) Inhibitors (Captopril (Capoten), Enalapril (Vasotec), Fosinopril (Monopril), Lisinopril (Prinivil, Zestril), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), Others), Angiotensin II Receptor Blockers (Candesartan (Atacand), Losartan (Cozaar), Valsartan (Diovan)), Angiotensin-Receptor Neprilysin Inhibitors (ARNIs) (Sacubitril/valsartan), If Channel Blocker (Ivabradine (Corlanor)), Beta Blockers (Bisoprolol (Zebeta), Metoprolol Succinate (Toprol XL), Carvedilol (Coreg), Others), Aldosterone Antagonists (Spironolactone (Aldactone), Eplerenone (Inspra), Diuretics, Furosemide (Lasix), Bumetanide (Bumex), Torsemide (Demadex), Chlorothiazide (Diuril)), Amiloride (Midamor Chlorthalidone (Hygroton) (Hydrochlorothiazide or HCTZ (Esidrix, Hydrodiuril), Others), Anticoagulants (Blood Thinners) (Cholesterol Lowering Drugs (Statins), Digoxin)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by key geographical regions (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.